Back to Browse Journals » Biologics: Targets and Therapy » Volume 6

Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study

Authors Cantini F, Niccoli L, Cassarà E, Kaloudi O, Nannini C

Published Date July 2012 Volume 2012:6 Pages 201—206

DOI http://dx.doi.org/10.2147/BTT.S31145

Received 23 February 2012, Accepted 30 March 2012, Published 12 July 2012

Fabrizio Cantini, Laura Niccoli, Emanuele Cassarà, Olga Kaloudi, Carlotta Nannini

Division of Rheumatology, Misericordia e Dolce Hospital of Prato, Prato, Italy

Purpose: The primary purpose of this study was to evaluate the proportion of psoriatic arthritis (PsA) patients maintaining clinical remission after adalimumab (ADA) dose reduction compared with patients with rheumatoid arthritis. Secondary purposes include evaluating the proportion of PsA patients who achieve remission, the duration of remission after ADA dose reduction, time to relapse, psoriasis course, and the frequency of adverse events at the end of follow-up.
Methods: This was a single-center, prospective, follow-up, case-control study of 76 consecutive patients (35 females, 41 males; mean age 46 ± 10.2 years) who met the classification criteria for psoriatic arthritis and required anti-tumor necrosis factor therapy according to Group for Research and Assessment of Psoriasis and Psoriatic Arthritis recommendations. The 76 patients were compared with 55 patients (40 females, 15 males; mean age 50 ± 11.6 years) who satisfied the American College of Rheumatology criteria for rheumatoid arthritis and received the same treatment. Case patients and controls were recruited from January 2008 to December 2010. At baseline, PsA patients and controls received 40 mg of ADA every other week, usually with methotrexate (10 to 20 mg/weekly). In the presence of clinical remission, ADA dose was reduced to 40 mg every 4 weeks in both groups.
Results: Fifty-three of the 76 (69.7%) PsA patients and 17 of the 55 (30.9%) rheumatoid arthritis (P < 0.019) controls achieved remission after a mean time of 5.1 ± 1.2 and 6.3 ± 1.6 months, respectively (P = nonsignificant). After halving the dose of ADA, 47 of the 53 (88.6%) PsA patients and three of the 17 (17.6%) controls maintained remission (P = 0.016) over a mean follow-up period of 28.9 ± 8.4 and 24.2 ± 6.4 months, respectively. No significant changes in Psoriatic Arthritis Severity Index scores were observed. The mean time to relapse was 8.3 ± 3.4 months in six case patients and 7.2 ± 4.2 in 14 controls (P = not significant). No serious adverse events occurred in either group.
Conclusion: Clinical remission is possible in a high percentage of patients with early PsA receiving ADA. Such remission is maintained in a high proportion of subjects after ADA dose halving, with relevant advantages in terms of patient compliance, drug-exposure risk, and economic burden.

Keywords: psoriatic arthritis, anti-TNF, adalimumab, remission, dose reduction

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients

Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassarà E, Susini M, Lenzetti I

Biologics: Targets and Therapy 2012, 6:5-12

Published Date: 29 December 2011

Readers of this article also read:

B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab

Wiesik-Szewczyk E, Olesinska M

Biologics: Targets and Therapy 2012, 6:347-354

Published Date: 26 September 2012

The therapeutic potential of RORγ modulators in the treatment of human disease

Chang MR, Goswami D, Mercer BA, Griffin PR

Journal of Experimental Pharmacology 2012, 4:141-148

Published Date: 12 October 2012

Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus

Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C

Journal of Experimental Pharmacology 2012, 4:149-155

Published Date: 23 October 2012

Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis

Thorlund K, Druyts E, Aviña-Zubieta JA, Mills EJ

Biologics: Targets and Therapy 2012, 6:417-427

Published Date: 3 December 2012

Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review

Colucci L, Bosco M, Ziello AR, Rea R, Amenta F, Fasanaro AM

Journal of Experimental Pharmacology 2012, 4:163-172

Published Date: 12 December 2012

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

Ansari J, Hussain SA, Ansari A, Glaholm J

Biologics: Targets and Therapy 2013, 7:39-46

Published Date: 28 February 2013